Halozyme Therapeutics, Inc. (0J2O.L) LSE
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Market Cap | 8.14B |
| Enterprise Value | 10.2B |
| P/E Ratio | 23.63 |
| PEG Ratio | -0.98 |
| Price/Sales Ratio | 5.42 |
| Price/Book Ratio | 37.11 |
| Enterprise/Revenue | 6.64 |
| Enterprise/EBITDA | 16.06 |
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | March 31, 2026 |
| Profit Margin | 0.23 |
| Operating Margin | 0.57 |
| Return On Assets | 0.13 |
| Return On Equity | 1.26 |
| Revenue | 1.4B |
| Revenue/Share | 12.77 |
| Gross Profit | 1.09B |
| EBITDA | 904.34M |
| Net Income | 316.89M |
| Diluted EPS | 2.56 |
| Total Cash | 318.62M |
| Total Cash/Share | 2.7 |
| Total Debt | 2.14B |
| Total Debt/Equity | 9.76 |
| Current Ratio | 2.76 |
| Book Value Per Share | 1.86 |
| 52-Week Change | 31.75 |
| 52-Week High | 70 |
| 52-Week Low | 30.09 |
| Moving Average 50 Days | 36.88 |
| Moving Average 200 Days | 37.43 |
| Average Volume | 1,670 |
| Shares Outstanding | 118.57M |
| % Held by Institutions | N/A |
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |